
The MenaQ7® Advantage: Unrivaled Proven Efficacy
MenaQ7® Vitamin K2 was created from a desire to substantially impact people’s health through all stages in life. Today MenaQ7® stands tall as the actual source material in over 22 published human clinical trials, validating the remarkable health benefits of Vitamin K2 as MK-7. Among these trials, some of the most groundbreaking, placebo-controlled, clinical trials (published in Osteoporosis International and Thrombosis and Haemostasias) unveiled market-changing outcomes for healthy postmenopausal women, who experienced positive bone and cardiovascular health outcomes after supplementing with 180 mcg/day of MenaQ7® Vitamin K2 over three years.
The proof is in the pudding, and the clinical studies where MenaQ7® was the source material provides you with the tools to effectively set your K2 product out from the crowd. The list below provides brief introduction to the significance of MenaQ7® Research:
- MenaQ7® Dose-Finding and Safety Study: This study established the optimal dose of MK-7 for activating vitamin K-dependent proteins in bone and vessel walls.
- MenaQ7® for Optimal Bioavailability: This study shows vitamin K2 as MK7 is more effective in contributing to vitamin K status in serum compared to K2 as MK-4.
- MenaQ7® for Children’s Health: Study in healthy prepubertal children showed support for children’s growing strong bones.
- MenaQ7® Fortified Yogurt Drink Study: A study on healthy individuals revealed that a yogurt drink fortified with MK-7 (MenaQ7®) significantly improved vitamin K status and markers of vascular health.
Latest news & videos

- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...

- Mobility & Joint
- MyCondro®
- News
- Jun 05, 2025
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by...

- MenaQ7®
- Mobility & Joint
- News
- Jun 02, 2025
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery...